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Most autosomal genetic causes of childhood-onset hypogammaglobulinemia are currently not well understood. Most affected individ-
uals are simplex cases, but both autosomal-dominant and autosomal-recessive inheritance have been described. We performed genetic
linkage analysis in consanguineous families affected by hypogammaglobulinemia. Four consanguineous families with childhood-onset
humoral immune deficiency and features of autoimmunity shared genotype evidence for a linkage interval on chromosome 4q.
Sequencing of positional candidate genes revealed that in each family, affected individuals had a distinct homozygous mutation in
LRBA (lipopolysaccharide responsive beige-like anchor protein). All LRBA mutations segregated with the disease because homozygous
individuals showed hypogammaglobulinemia and autoimmunity, whereas heterozygous individuals were healthy. These mutations
were absent in healthy controls. Individuals with homozygous LRBAmutations had no LRBA, had disturbed B cell development, defec-
tive in vitro B cell activation, plasmablast formation, and immunoglobulin secretion, and had low proliferative responses. We conclude
that mutations in LRBA cause an immune deficiency characterized by defects in B cell activation and autophagy and by susceptibility to
apoptosis, all of which are associated with a clinical phenotype of hypogammaglobulinemia and autoimmunity.Introduction
In 86% of cases, childhood-onset agammaglobulinemia is
an X-linked condition (XLA, [MIM 300755]) affecting
male offspring.1 XLA is caused by mutations in BTK
(MIM 300300), which encodes a signaling molecule down-
stream of the B cell antigen receptor,2 and is characterized
by the lack of peripheral B cells (<1%).1 The remainder of
agammaglobulinemias are rare autosomal-recessive (AR)
traits; to date, six genes with mutations causing agamma-
globulinemia have been described.3,4
In contrast to agammaglobulinemias, childhood-onset
hypogammaglobulinemias are characterized by the pres-
ence of B cells in the periphery and by some residual
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of, e.g., nephrosis, enteric protein loss, medication (immu-
nosuppressive or antiepileptic drugs), or connatal infec-
tion, such as HIV or measles. In addition, primary T cell
deficiencies combined with either the lack of peripheral
B cells or a functional defect of persisting B cells (such as
T-Bþ severe combined immune deficiency or immunodefi-
ciency, centromeric instability, and facial anomalies [ICF]
syndrome [MIM 601457 and 242860, respectively]) might
also include childhood-onset hypogammaglobulinemia as
part of the phenotype.5,6
In adults, primary persistent hypogammaglobulinemia
is either diagnosed as being caused by class-switch-recom-
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608184) or diagnosed as common variable immune defi-
ciency (CVID), which is a diagnosis of exclusion. Hence,
it is not surprising that CVID has a heterogeneous clinical
and laboratory presentation.8 Affected individuals present
with low IgG and IgA levels, whereas IgM levels can be low
or normal.9 Most suffer from recurrent bacterial infec-
tions.10 Major complications include autoimmune, lym-
phoproliferative, and granulomatous diseases, which are
each seen in 20%–30% of CVID-affected individuals.11
Fewer than20%of adult individualswith aprimaryhypo-
gammaglobulinemia have an affected relative.9 Reported
families have either autosomal dominant (AD) or AR
inheritance.12 Previously identified genetic defects associ-
ated with AR hypogammaglobulinemia are biallelic muta-
tions in genes involved in B cell stimulation (such genes
are CD19,13 MS4A1,14 CD81,15 CR2,16 and TNFRSF13C17
[MIM 613493, 613495, 613496, 610927, and 613494,
respectively]) and a gene involved in T cell costimulation
(ICOS [MIM 607594]).18 Interestingly, these individuals do
not often have autoimmune phenomena, which are other-
wise frequently seen in individuals with CVID. Polymor-
phisms in TNFRSF13B (encoding TACI, [MIM 240500])
and MSH5 (MIM 603382) have been associated with AD
and simplex cases of CVID.19–22 For TNFRSF13B,most indi-
viduals with biallelic mutations develop CVID, whereas
those with single-allele mutations are at a substantially
increased risk of developing CVID and autoimmune
phenomena.23 Large families with suggested dominant
inheritance of CVID have been published. Genetic linkage
studies in such families have found evidence of causative
mutations on chromosome arms 4q24 and 16q,25 but
disease-associated genes have not been identified.
In this study, we used a positional approach by seeking
causative mutations that are found in individuals with
severe, early-onset humoral immune deficiency and auto-
immunity. By genome-wide SNP typing, genetic linkage
analysis, and DNA sequencing of 16 families with putative
recessive inheritance, we were able to find individuals with
four distinct homozygous mutations in the gene encoding
LRBA (lipopolysaccharide responsive beige-like anchor
protein [MIM 606453]) in chromosomal region 4q31.
Because LRBA expression has been found to be upregulated
in cancer cells, it has been suggested that the protein acts
as a positive regulator of cell survival by promoting prolif-
eration and by preventing apoptosis.26 Here, we show that
individuals with homozygous LRBAmutations have severe
defects in B cell development and activation and in
autophagy. B cell lines from these individuals show an
increased susceptibility to apoptosis. Accordingly, LRBA
has unanticipated functions in B cells, which are essential
for normal development and humoral immune responses.
Material and Methods
Affected Individuals and Controls
Our study focused on five affected individuals from four consan-
guineous families for which genetic linkage evidence is the stron-The Amegest. Family A is of Arab origin and was followed at the Meyer’s
Children Hospital, Rappaport School of Medicine (Haifa, Israel).
Family B is of Sicilian origin and was under the care of the Univer-
sity Hospital Center of Lie`ge (Lie`ge, Belgium). Families C and D
are from Iran and were followed at the Children Medical Center
(Tehran, Iran). The affected individuals in families A, B, and C
are alive, whereas the affected individual in family D is deceased.
All affected individuals were diagnosed with childhood-onset
CVID.
In addition, we analyzed 100 European, 145 Arabic (17 from the
village of family A and 128 from elsewhere), and 233 Iranian
healthy control samples to exclude the possibility that the
detected mutations represent rare benign polymorphisms. For
functional experiments, control samples from unrelated, healthy
individuals were used unless otherwise specified.
All study participants gave their informed consent as appro-
priate under approved protocols from local institutional review
boards. The research was conducted at University College London,
Karolinska Institutet Stockholm, and the Universities of Freiburg,
Brescia, and Oxford under approved protocols (#04/Q0501/119
for affected individuals, #07/H0720/182 for family members,
and #08/H0720/46 for healthy controls).Genotyping
Families A and B and the two Italian families were genome-wide
typed with the Affymetrix (Santa Clara, CA, USA) GeneChip
Human Mapping 250K Nsp Array (GEO Platform GPL3718)
according to previously described methods.27 Fine mapping with
selected microsatellite markers on chromosomes 4, 5, and 12
was performed in family A according to published protocols.24
Samples from 12 simplex Iranian cases, including the affected
individuals from families C and D, had been previously genotyped
with the older Affymetrix Human Mapping 10K Array Xba 142
(GEO Platform GPL2641).Genetic Linkage Analysis
To identify perfect or near perfect intervals in families A and B, we
used the in-house software ‘‘findhomoz’’ described previously.27
We used a modified version of ‘‘findhomoz’’ to reanalyze the
SNP chip data from the 12 Iranian simplex cases to identify
regions for which multiple individuals shared the same homozy-
gous haplotype.
A marker or interval of markers segregates perfectly with reces-
sive inheritance under consanguinity if the affected individuals
are homozygous with the same genotype or haplotype, respec-
tively, and the unaffected individuals have different genotypes
or haplotypes. For the family structures of A, B, C, andD, the segre-
gation is near perfect if there is one exception among the children.
An exception could be an affected individual who does not share
the same homozygous genotype (a ‘‘phenocopy’’) or an unaffected
individual who shares the same homozygous genotype (‘‘nonpe-
netrant’’). We limited our search for near-perfect intervals to the
nonpenetrant type of exception.Mutation Detection
Genomic DNA and cDNA were obtained from peripheral-blood
mononuclear cells (PBMCs) of affected individuals, unaffected
family members, and controls. We sequenced either gDNA or
cDNA for 20 different genes with immune function in the linkage
regions from chromosomes 4, 5, and 12 (Table S1, available
online) by using standard protocols. We sequenced LRBA cDNArican Journal of Human Genetics 90, 986–1001, June 8, 2012 987
with 16 different overlapping PCR products. We sequenced LRBA
gDNAwith 61 pairs of oligonucleotides to amplify 58 exons of the
chronologically first transcript (we used RefSeq NM_006726.2; the
current version is NM_006726.4) with the longer coding region.
Gene sequencing was according to the exon-intron structure sug-
gested by the Ensembl record for transcript ENST00000357115,
which has 100% sequence identity with NM_006726.4 except
for the length of the poly(A) tail.Reference Sequences of LRBA
The two reference transcripts for LRBA are NM_001199282.2
and NM_006726.4. No version of the reference sequence
NM_001199282 was available at the time we did the sequencing.
NM_001199282.2 produces a shorter protein product than does
NM_006726.4 by omitting an exon of NM_006726.4 and one
serine near the C terminus. We suggest that the primary protein
product probably does not contain that exon.
The exon included in NM_006726.4 but omitted in
NM_001199282.2 can be unambiguously identified by the
Ensembl identifier ENSE00001249966. It comprises bases 6,291–
6,323 of the LRBA reference RNA NM_006726.4 and leads to
in-frame predicted translation of amino acids 2,016–2,026
(VCIFKLRENSK) in NP_006717.2. It is exon 39 in the intron-
exon structure suggested by the Ensembl record for transcript
ENST00000357115, which we used to guide the sequencing. We
therefore refer to ENSE00001249966 as exon 39, but it is exon
40 in the GenBank record for NM_006726.4.
The sequence NM_006726.4 is a composite of at least four
GenBank submissions that are not entirely consistent with one
another. The evidence given by the National Center for Biotech-
nology Information (NCBI) Evidence Viewer in favor of inclusion
of exon 39 is the GenBank sequences M83822.1 and AF216648.2.
The sequence M83822.1 was published as part of the initial gene
discovery. The sequence AF216648.2 replaced the much shorter
sequence AF216648.1, which does not contain exon 39. The
methods used for the identification of the sequence AF216648.1
were published, wherein the submitters reference the GenBank
record M83822.1 but do not claim to have directly sequenced
the cDNA. The GenBank record AF216648.2 explicitly states that
it was not published in a journal. The lack of published evidence
for prior sequencing of exon 39 in normal gene expression and
the observation that exon 39 is skipped in all healthy donors
sequenced in this study suggest that the primary transcript or tran-
scripts of LRBA do not contain exon 39. Using Entrez for the align-
ment of NP_006717.2 to NCBI’s Conserved Domain Database
shows that the insertion of these 11 amino acids causes a gap in
the alignment to the canonical sequence representing DUF1088,
a domain of unknown function found in several proteins that
also contain BEACH domains.Determination of the Boundaries of the Large
Deletion in P5
Standard PCR amplification and sequencing of LRBA were per-
formed. In brief, 50 ng of genomic DNA was used in PCR employ-
ing specific primers with the following conditions: 95C (2 min)
for one cycle, 95C (15 s), alignment (30 s), and 72C (1 min)
for 35 cycles each, and a final extension of 72C (10 min). A
long PCR kit (Roche, Basel, Switzerland) was used for long-range
PCR amplification with the following conditions: 92C for one
cycle, 92C (15 s), 56C (30 s), and 68C (6 min) for 10 cycles
each, 92C (15 s), 56C (30 s), and 68C (6 min) for 20 cycles988 The American Journal of Human Genetics 90, 986–1001, June 8,each (20 s was added for each successive cycle), and a final exten-
sion of 68C (10 min). The PCR products were gel purified (with
a gel extraction kit [QIAGEN, Stockholm, Sweden]) and sequenced
at the Macrogen Company (Seoul, South Korea). The sequences
were analyzed with Lasergene software (DNAStar, Madison,
WI, USA).
Generation of Epstein-Barr-virus Cell Line and LRBA
Immunoblot
PBMCs from affected individuals and healthy donors were
cultured in RPMI 1640 supplemented with 2 mM L-glutamine
(Lonza Biologics, Basel, Switzerland), 50 U/ml penicillin, and
50 mg/ml streptomycin (GIBCO, Carlsbad, CA, USA) at a density
of 1 3 106 cells/ml in the presence of 10 mg/ml of phytohemaglu-
tinin (PHA [Sigma-Aldrich, St. Louis, MO, USA]) and a 1:2 dilution
of Epstein-Barr virus (EBV) supernatant obtained from the
marmoset cell line B95-8. Cells were maintained in culture for
1 month so that they would immortalize. EBV cell lines were
used for immunoprecipitation and immunoblots.
LRBA levels were determined by immunoblot according to
standard procedures. In brief, 25 mg of protein extracts from
EBV cell lines was loaded onto a gradient gel (9%–18% polyacryl-
amide) and transferred onto polyvinylidene difluoride (PVDF)
membranes for 4 hr at 130V in 5% isopropanol transfer buffer.
Anti-LRBA (Sigma-Aldrich, St. Louis, MO, USA), which recognizes
the amino acids 906–1,038, was used for the detection of a band of
approximately 319 kDa.
B Cell Immunophenotyping
PBMCs were isolated by centrifugation through a Ficoll step
gradient and stained for cell-surface-marker expression with the
use of fluorochrome-conjugated antibodies against CD19 (APC-
H7), CD10 (FITC), CD27 (PE-Cy5.5), CD38 (PE-Cy7), BAFF-R (PE
[all from Becton Dickinson, Franklin Lakes, NJ, USA]), IgM
(Cy5), IgA (Alexa 647), and IgG (FITC [all from Jackson Immunor-
esearch, West Grove, PA, USA]). A total of 5 3 105 cells were
acquired with a FACS-Canto II flow cytometer with FACS-Diva
software (BD Biosciences) and analyzed with FlowJo (Treestar,
Ashland, OR).
B Cell Activation, Immunoglobulin Secretion,
Plasmablast Generation, and Proliferation Detection
PBMCs of affected individuals and healthy controls were isolated
by density gradient with LymphoprepTM (Axis-Shield). Naive B
cells were separated from PBMCs by negative depletion with the
use of Naive Isolation Kit II (Miltenyi Biotec, Bergisch-Gladbach,
Germany). For stimulation, 50,000 naive B cells were cultured in
U96-well plates in 250 ml of RPMI 1640 supplemented with fetal
calf serum (FCS), L-glutamine, penicillin, and streptomycin. Cells
were stimulated with 2.5 mg/ml of anti-human IgM (MP Biomedi-
cals), 1 mg/ml of soluble recombinant CD40L (Enzo Life Sciences),
2.5 mg/ml of CpG oligodeoxynucleotides 2006 (InvivoGen, San
Diego, CA, USA), and 75 ng/ml of recombinant BAFF (Peprotech,
Rocky Hill, NJ, USA). Cells were maintained in culture for
13 days, and culture supernatants were collected for the determi-
nation of IgG production by ELISA (Bethyl Laboratories, Mont-
gomery TX, USA).
In a second approach, 1 3 105 PBMCs were cultivated in
U-bottom 96-well plates in Iscove’s modified Dulbecco’s
medium (Biowest, East Sussex, UK) supplemented with 10% FCS
(Lonza Biologics, Basel, Switzerland), nonessential amino acids2012
(Invitrogen), fatty-acid supplement (Invitrogen), insulin (Sigma-
Aldrich), and transferrin. The cells were activated by the addition
of a soluble adiponectin-CD40L fusion protein combined with
IL21-Fc or IL4 as described previously.17 After 4 days, cells were
transferred to new wells in fresh medium and cultivated for an
additional 3 days. Supernatants were tested for IgA, IgM, and
IgG levels by sandwich ELISA with the use of goat anti-human
Ig as capture and alkaline phosphatase-conjugated isotype-specific
detection antibodies (Jackson Immunoresearch, West Grove,
USA). The phenotype of activated B cells was analyzed by flow
cytometry; cells were stained as described previously17 with anti-
bodies specific to CD19, CD38, CD138, BAFF-R, CD43, and IgD
(all Becton Dickinson, Franklin Lakes, NJ, USA), CD10 (Beckman
Coulter, Brea, CA, USA), IgA, IgG, and IgM, (Jackson Immunore-
search), and CD27 (Biolegend, San Diego, CA, USA).
For proliferation assays, PBMCs were resuspended at 1 3
106 cells/ml in supplemented RPMI, and 1.5 3 105 cells were
then added in triplicates into 96-well plates and stimulated with
10 mg/ml of Pokeweed mitogen (PWM [Sigma-Aldrich]). Cultures
were incubated at 37C for 72 hr in a humidified atmosphere con-
taining 5% CO2. Proliferation was measured by the addition of
1 mCi/well of 3H-thymidine (Perkin-Elmer, Waltham, MA) for
the last 18 hr of incubation. Cells were harvested onto glass-fiber
filters (Wallac Oy, Turku, Finland) and resuspended in Betaplate
Scint cocktail (Perkin Elmer Life Sciences, Cambridge, UK), and
thymidine incorporation was determined with a 1205 Betaplate
liquid scintillation counter (Perkin Elmer). Proliferative responses
are expressed as stimulation index (SI) ¼ net counts per minute
(cpm) of PWM-stimulated cultures/cpm of unstimulated cultures.Apoptosis Assay
Apoptosis levels were determined in EBV cells cultured under
serum deprivation for 6 hr (13 106 cells/ml). After starvation, cells
were harvested, and apoptosis was measured by Annexin V and
propidium iodide (PI) staining (eBioscience, San Diego CA, USA).
Immediately after staining, 10,000 events were acquired in an
LSR II flow cytometer and were analyzed for the determination
of the percentage of cells in early apoptosis (positive for Annexin
V and negative for PI).Transmission Electron Microscopy
Cells were fixed in 2.5% glutaraldehyde (Ladd, Burlington,
Vermont, USA) in 0.1 M phosphate buffer (pH 7.4) at room
temperature for 30 min. The cells were then transferred to a micro-
centrifuge tube and further fixed overnight in the refrigerator.
After fixation, cells were rinsed in 0.1 M phosphate buffer and
centrifuged. The pellets were then postfixed in 2% osmium
tetroxide (TAAB, Berkshire, England) in 0.1 M phosphate buffer
(pH 7.4) at 4C for 2 hr, dehydrated in ethanol and then in
acetone, and embedded in LX-112 (Ladd). Ultrathin sections
(approximately 40–50 nm) were cut by a Leica ultracut UCT (Leica,
Wien, Austria). Sections were contrasted with uranyl acetate and
later with lead citrate and were examined in a Tecnai 12 Spirit
Bio TWIN transmission electron microscope (Fei Company,
Eindhhoven, the Netherlands) at 100kV. Digital images were taken
with a Veleta camera (Olympus Soft Imaging Solutions, GmbH,
Mu¨nster, Germany).28Detection of Autophagic Flux
ImageStream (Amnis, Seattle, US), a multispectral flow cytometer
combining standard microscopy with flow cytometry, was usedThe Amefor the analysis of autophagic flux. PBMCs or whole blood was
stained with the violet LIVE/DEAD marker (L34955 Component
A, Invitrogen, Carlsbad, CA, USA), a red lysosome-specific dye
(LysoID, Enzo Life Sciences, Lausen, Switzerland), and a CD19
antibody. Cells were fixed and permeabilized (eBioscience
kit) and stained with mouse-anti-LC3 (Nanotools, Teningen,
Germany) and goat-anti-mouse IgG-AlexaFluor488 (Invitrogen).
Single-stained controls were included for compensation. After
image acquisition, the software package IDEAS 4.0.735 was used
for analyzing live cells for colocalization of LC3 and lysosomes.
We calculated autophagy levels by measuring percent colocaliza-
tion (bright detailed similarity) of LC3 and LysoID gated on
CD19þLC3þLysoIDþ live cells. This analysis gives an estimation
of the relative number of autophagolysosomes per cell in a sample
of more than 20,000 cells and yields a powerful assessment of
autophagic flux.Results
Case Reports
In family A (Figures 1A and Figure S1), the index case
(individual P1) was born in 1991 to first-cousin Arab
parents. At 1 year of age, he presented with idiopathic
thrombocytopenic purpura (ITP). At age 5, he was hospital-
ized with pleuropneumonia. A clinical workup (Table 1)
revealed low immunoglobulin levels and led to the
diagnosis of CVID and the initiation of intravenous immu-
noglobulin (IVIG) replacement. He progressively devel-
oped chronic lung disease; his computed tomography
(CT) scans have shown bilateral bronchiectasis since was
6 years old. Lung biopsies were obtained and revealed
a lymphoid interstitial pneumonia (LIP). Since the age of
2 years, his growth has been severely retarded (both
weight and height are below the second percentile), and
he has presented with significant clubbing. Recently, he
developed strabismus as a result of abducens nerve palsy
along with hemiplegia. During our study, a magnetic
resonance image (MRI) of his head showed a cerebral
mass, which is currently being evaluated for granuloma
formation.
At 1 year of age, his sister (individual P2; Figure 1A and
Figure S1), born in 1997, also had ITP, which was self-
limiting. At 2 years of age, she developed asthma, which
was satisfactorily treated with inhaled steroids. After devel-
oping serous otitis media, she underwent adenoidectomy
and bilateral insertion of ventilation tubes at age 9. In
the following year, a massive pneumonia along with locu-
lated empyema required surgical intervention, including
thoracotomy and drainage. Cultures from the pleural effu-
sion revealed Streptococcus pneumoniae and Aspergillus.
Low immunoglobulin levels were detected (Table 1), and
she was treated with antibacterials, antifungals, and
IVIG. Furthermore, she suffered from chronic lung disease
with bilateral bronchiectasis. She was small for her age
(both weight and height were below the fifth percentile
since the age of 2). When she was 11 years old, reactive
monoarthritis emerged in her right knee, and it responded
well to local steroid injections.rican Journal of Human Genetics 90, 986–1001, June 8, 2012 989
Figure 1. Mutations in LRBA
Shaded figures are affected individuals homozygous for a mutation in LRBA. Half-shaded figures are unaffected individuals heterozygous
for a mutation in LRBA.
(A) Family A with two affected individuals showing a homozygous missense p.Ile2657Ser substitution.
(B) Family B with one affected individual who had homozygous nonsense substitution p.Arg1683*.
(C) In family C, the amino acid substitution was nonsense: p.Glu59*.
(D) The affected individual from family D has a large homozygous deletion including exons 1 and 2 and ~60 kb upstream and ~50 kb
downstream. The parents in family D are heterozygous for the deletion, but the unaffected sibling does not carry the deletion.Individual P3 (family B; Figure 1B), born in 1982, is of
Sicilian origin. The parents were first cousins once
removed. The first symptoms were recurrent warts and
perineal molluscum contagiosum at age 12 and an
increased frequency of mild respiratory infections. At age
16, he was hospitalized with ITP, lymphadenopathy, auto-
immune haemolytic anemia (AIHA), atrophic gastritis with
autoantibodies against intrinsic factor, and a submaxillar
abscess (Staphylococcus aureus and Streptococcus viridians).
An immunological workup revealed a moderate IgG hypo-
gammaglobulinemia and complete IgA deficiency (Table 1)
but a normal neutrophil count; IVIG replacement was
started. He also had severe diarrhea in the absence of any
detectable bacterial or parasitic infection. After undergoing
a colonoscopy, he was diagnosed with a severe nonspecific
colitis. During the following years, he developed severe990 The American Journal of Human Genetics 90, 986–1001, June 8,recurrent pneumonias, including several interstitial pneu-
monias, sputum cultures of which did not grow any path-
ogen. At the time of the infections, IgM was intermittently
elevated (5–8 g/l, data not shown) and swelling of hilar and
mediastinal lymph nodes occurred. Biopsies of these
lymph nodes were obtained, and the histological analysis
showed a mixed lymphoid follicular hyperplasia with the
absence of the follicular mantle zone. A pulmonary
workup showed a lymphoid interstitial pneumonia and
bronchiectasis. The interstitial lung disease was treated
with methylprednisolone. Attempts to taper steroids
were frequently associated with relapses, and long-term
treatment with infliximab was initiated and allowed
the discontinuation of methylprednisolone. Infliximab,
however, led to little improvement of the chronic diarrhea.
At age 26, the individual underwent an episode of seizures2012
Table 1. Laboratory Values for Affected Individuals with Homozygous Mutations in LRBA
Affected Individual
P1 P2 P3 P4 P5
Substitution p.Ile2657Ser p.Ile2657Ser p.Arg1683* p.Glu59* not applicable
Lymphocyte counts (first measurement)
Age at measurement 5 years 14 years 29 years 19 years 19 years
CD3 (cells/ml) 900 (900–4,500) 2,073 (800–3,500) 2,350 (700–2,100) [ 5,716 (700–2,100) [ 355 (700–2,100) Y
CD4 (cells/ml) 685 (500–2,400) 767 (400–2,100) 1,290 (300–1,400) 1,061 (300–1,400) 262 (300–1,400) Y
CD4 CD45RA N.D 179 (230–770)a 201 (27–833)b 72 (27–833)b N.D
CD4 CD45RO N.D 553 (240–700)a 887 (167–670)b [ 588 (167–670)b N.D
CD8 (cells/ml) 380 (300–1,600) 1,200 (200–1,200) 1,032 (200–900) [ 4,707 (200–900) [ 165 (200–900) Y
CD8 CD45RA N.D 1,003 (240–710)a [ 941 (19–508)b [ 1,991 (19–508)b [ N.D
CD8 CD45RO N.D 473 (10–142)b [ 627 (15–275)b [ 374 (15–275)b [ N.D
Lymphocyte counts (second measurement)
Age at measurement 5 years 10 years 16 years 16 years 19 years
NK cells (cells/ml) 260 (100–1,000) 190 (70–1,200) 35 (70–1,200) Y N.D. N.D.
CD19 (cells/ml) 280 (200–2,100) 300 (200–600) 219 (200–600) 69 (200–600) Y 121 (100–500)
Switched memory B cells
(CD19þ CD27þ IgM,
% of total B cells)
0 (3.9–16.2) Y 1 (3.85–16.5) Y 0.8 (4–22.8) Y 0.89 (4–22.8) Y N.D.
Immunoglobulin levels
Age at measurement 5 years 10 years 16 years 7 years 19 years
IgG (g/l) 1.6 (4.9–16.1) Y 1.8 (5.4–16.1) Y 3.23 (6.0–16.0) Y 0.34 (5.4–16.1) Y 3,4 (6.0–16.0) Y
IgM (g/l) 0.22 (0.5–2) Y 0.16 (0.5–1.8) Y 0.72 (0.5–1.9) 0.2 (0.5–1.8) Y 0.2 (0.5–1.9) Y
IgA (g/l) 0.1 (0.4–2) Y 0 (0.7–2.5) Y 0 (0.8–2.8) Y 0.1 (0.5–2.4) Y 0 (0.8–2.8) Y
Age-adapted reference ranges are shown in parentheses. Y indicates a value below the reference ranges, and [ indicates a value above the reference ranges. Refer-
ence ranges that are not marked were obtained from Comans-Bitter et al.29 The following abbreviations are used: N.D., not done; and NK, natural killer.
aReference range obtained from Shearer et al.30
bReference range obtained from Mayo Medical Laboratories.caused by a pseudotumoral lesion in the right temporal
lobe. After surgical removal of the lesion, he recovered
and the histopathological workup revealed a granuloma-
tous infiltration with T cells, plasma cells, and macro-
phages but showed low B cell numbers. Recently, the
seizures recurred, but no lesion was detectable in an MRI.
In Iranian family C with first-cousin parents (Figure 1C),
individual P4, a male, was born in 1993 and presented
with frequent upper-respiratory-tract infections, several
episodes of pneumonia, AIHA, and ITP at the age of 2 years.
Although he experienced recurrent respiratory and gastro-
intestinal infections, the diagnosis of CVID was not made
until he was 7 years old, when he developed severe lower-
respiratory-tract infections along with finger clubbing,
hepatosplenomegaly, and failure to thrive. On the basis
of these clinical findings and his low immunoglobulin
levels (Table 1), regular IVIG replacement therapy was
started. A pulmonary workup revealed an obstruction of
the small airways and bronchiectasis. During 10 years of
follow-up observation, he developed recurrent conjuncti-The Amevitis and urticaria and a cor pulmonale with consecutive
right-heart failure. However, the predominant clinical
problems were ITP, AIHA, and an autoimmune enterop-
athy (which can be classified as Crohn disease), which
was confirmed by gastrointestinal histology. Currently,
he is being treated with IVIG replacement and antibiotic
prophylaxis.
In family D, individual P5 (Figure 1D), born in 1983, was
previously described.31 She was an Iranian woman who
died at the age of 19 after respiratory failure. At 2 years
of age, her medical problems began with allergic dermatitis
followed by recurrent, chronic diarrhea and frequent
upper-respiratory-tract infections, including sinusitis and
otitis media. At age 15, after an episode of pneumonia,
she was initially diagnosed with selective IgA and IgG2
deficiency. Within 2 years, her serum levels of IgG
and IgM declined gradually, she developed bronchiectasis,
and she was diagnosed with CVID. Additionally, she
had autoimmune phenomena, hypothyroidism, and
myasthenia gravis. However, there were no signs of ITPrican Journal of Human Genetics 90, 986–1001, June 8, 2012 991
Figure 2. Homozygous LRBA Mutations Lead to Lack of Protein
(A) A schematic representation of LRBA shows domains and location of mutations at the protein level.
(B) Protein extracts of Epstein-Barr virus (EBV)-transformed B cell lines (EBV cells) from individuals P1, P2, and P3, from three hetero-
zygous members of family A, and from two controls were loaded into a polyacrylamide gel. EBV cells from homozygous affected indi-
viduals show an absence of LRBA, whereas both heterozygous individuals and the healthy controls show protein expression.
(C) EBV cell lines from two affected individuals and three healthy donors were subjected to starvation. The proportion of early apoptotic
cells was determined with Annexin V and propidium iodide staining. Both the percentage of early apoptotic EBV cells after starvation
and the increase in apoptosis after starvation were significant (p values are 0.0172 and 0.0057, respectively, as determined by Welch t
tests). We calculated the increase in apoptosis by subtracting the amount of unstarved EBV cells from the amount of starved EBV cells
for both affected individuals and controls.or AIHA. Because of chronic diarrhea and growth
retardation, a gastrointestinal biopsy was performed and
showed intestinal inflammation and subtotal villous
atrophy.
Genotyping Families A and B
The analysis of family A SNP data identified two intervals
(larger than 1 Mb) that segregated perfectly with disease
status on chromosomes 4q and 5q. A perfectly segregating
haplotype in family A had a multipoint LOD score of at
least 2.08. There was also a near-perfect interval on 12q.
The intervals on 4q, 5q, and 12q contain at most 81, 80,
and 107 genes or predicted genes, respectively (Table S1).
Genotyping with microsatellites confirmed the perfect
segregation on 4q and showed that the linked interval
extended from 141.9 to 155.0 Mb at the very least and
from141.4 to 157.7Mb at themost (Figure S1). The interval
on 4q did not overlap with the 4q interval described previ-
ously in a dominantCVID family.24Microsatellite genotyp-
ing also confirmed the intervals on 5q and 12q.992 The American Journal of Human Genetics 90, 986–1001, June 8,Before finding any mutation, we genotyped family B by
using SNP chips. The largest perfectly segregating interval
in family B was between 140.8–162.4 Mb on chromosome
4 and contained the largest perfect interval for family A.
The multipoint LOD score was at least 1.36 in pedigree B,
giving a total multipoint LOD score of at least 3.44 for
this interval on chromosome 4q. Other than the shared
large interval on chromosome 4q, there was no overlap
between the large perfect intervals for family B (chr14:
65.7–82.7 Mb and chr21: 33.2–39.4 Mb) and other perfect
or near perfect intervals for family A (chr5: 174.8–177.8
Mb and chr12: 103.4–111.0 Mb).
Homozygous Mutations in LRBA in Families A and B
Within the linkage interval on chromosome 4q, the eighth
gene that we sequenced in family A was LRBA. We found
a homozygous missense mutation, c.7970T>G, which
introduces the amino acid substitution p.Ile2657Ser in
exon 54 in individuals P1 and P2 (Figure 1A). All six unaf-
fected members in family A were heterozygous for2012
Table 2. Summary of the LRBA Mutations
Affected Individual Substitution Mutation Exon Accessiona
P1 p.Ile2657Ser c.7970T>G 54 ss479152582
P2 p.Ile2657Ser c.7970T>G 54 ss479152582
P3 p.Arg1683* c.5047C>T 30 ss479152581
P4 p.Glu59* c.175G>T 3 ss479152583
P5b not applicable g.152211739_152222852del111114 1–2del nstd59
aAccession numbers are for entries in dbSNP (P1–P4) or dbVar (P5).
bFor the deletion in P5, the positions are with respect to chromosome 4 (NCBI build 36).p.Ile2657Ser. We identified one more heterozygous
healthy individual by sequencing DNA from 17 additional
individuals, some of whom are relatives and all of whom
reside in the same village as family A. DNA samples of
128 healthy donors of Arabic heritage were subsequently
sequenced for exon 54 and gave only wild-type results,
suggesting that p.Ile2657Ser is not a benign variant. In sil-
ico analysis of the p.Ile2657Ser substitution was performed
with the bioinformatics tools SIFT32 and PolyPhen.33 SIFT
predicted that the mutation is deleterious and has a most
extreme possible score of 0.00. PolyPhen did not concur
with this prediction, but the fact that PolyPhen used fewer
than ten sequences homologous to LRBA limited its predic-
tive power. Multiple alignment of homologs from several
species shows that p.Ile2657 is a highly conserved residue
(Figure S2).
To investigate whether p.Ile2657Ser affected LRBA
levels, we performed immunoblot analysis in protein
extracts from EBV cell lines from two affected homozygous
individuals, three heterozygous individuals from family A,
and two healthy controls (Figure 2B). No LRBA was
detected in the affected individuals by immunoblot with
the antibody HPA023597, which was raised against amino
acids 906–1038 of LRBA. EBV cell lines from heterozygous
individuals showed protein levels comparable to the vari-
able amount of LRBA in healthy donor cells (Figure 2B).
Because the data from family A strongly suggested LRBA
as a candidate gene, we chose to sequence LRBA in family
B. We found that the index case (P3) in family B has
a homozygous c.5047C>T mutation, which introduced
a stop codon (p.Arg1683*) in exon 30 of LRBA, and that
the four unaffected members of family B were heterozy-
gous for this mutation (Figure 1B). As in family A, no
LRBA was detected in EBV cell extracts of the affected indi-
vidual (Figure 2B). Two hundred alleles from European
healthy controls were sequenced for exon 30, and no
mutation was found.
Additional Genetic Analysis and Sequencing
At this stage, we had evidence that homozygous mutations
in LRBA might cause an early-onset form of hypogamma-
globulinemia. We therefore analyzed genotype data and
sequenced LRBA in a total of 14 additional individuals
(12 Iranians and two Italians) for whom autosomalThe Amerecessive (AR) CVID was suspected because of the early
onset of symptoms and, in most cases, a consanguineous
family structure. We sought other affected individuals
with homozygous chromosome 4q intervals overlapping
LRBA.
P4 in family C was homozygous for 112 consecutive
markers in chr4: 140.8–172.4 Mb, whereas P5 in family D
was homozygous for 104 consecutive markers in chr4:
136.7–164.2 Mb. For each of the two affected individuals,
these regions were among the five longest homozygous
intervals across all autosomes.
Ten additional Iranian simplex cases were each homozy-
gous for 6–15 consecutive markers spanning LRBA in
intervals of sizes ranging from 0.5 to 3.0 Mb. Each of these
individuals had much longer homozygous intervals that
did not contain LRBA. We concluded that P4 and P5 had
strong evidence in favor of an LRBA mutation, whereas
the other ten simplex cases had weak genotype evidence
consistent with a mutation.
Two Italian families had perfectly segregating intervals
of 60 markers spanning chr4: 151.4–152.5 Mb and 42
markers spanning chr4: 151.5–152.3 Mb, respectively.
These intervals contain the majority of LRBA but not the
entire gene. Because these two families were genotyped
with the denser 250K mapping array, we can be confident
of the homozygosity of the affected individuals, but the
homozygous intervals are more than an order of magni-
tude shorter than the perfectly segregating intervals in
families A and B. We concluded that there was enough
evidence to justify sequencing LRBA in the affected indi-
viduals of these two families.
Sequencing and deletion assays (Figure S3) revealed
homozygous mutations in the affected individuals from
families C and D. Individual P4 from the Iranian family
C (Figure 1C) had a homozygous LRBA mutation gener-
ating a stop codon in exon 1 (c.175G>T [p.Glu59*]). This
mutation was absent in 233 Iranian controls as determined
by local sequencing. Individual P5 from the Iranian family
D had a homozygous deletion of 111,114 bp (Figure 1D),
including exons 1 and 2 and about 60 kb upstream and
50 kb downstream of these exons (the identification of
the deletion boundaries is described in Figure S3 and Table
S2). We identified the exact breakpoint of the deletion by
directly sequencing a 2.5 kb product amplified after therican Journal of Human Genetics 90, 986–1001, June 8, 2012 993
Figure 3. Phenotypic Characterization of B Cells
PBMCs were gated for CD19þ CD20þ B cells (A) and were analyzed for IgM, CD27 (B), and BAFF-R expression (C), for CD10 and CD38
expression for the detection of transitional B cells (D), and for IgA and IgG expression for the detection of switched-memory B cells (E).
P1 and P3 have fewer B cells than the healthy control analyzed in parallel (A). In addition, the IgMlow CD27, the IgMþ CD27þ
marginal-zone, and the IgM CD27þ switched-memory B cell subsets are smaller, whereas the IgMhi CD27 B cell subset is larger,
than in the control (B). BAFF-R expression is higher than in the control (BAFF-R mean fluorescence intensity of P1 ¼ 2,476; P2 ¼
1,978; HD ¼ 1,378). The proportion of CD10þ CD38þ transitional B cells in P1 is similar to that in the control (D), whereas IgA- or
IgG-expressing switched-memory B cells are lacking (E).use of primer pairs P11 and P18 (Table S2). Other members
of families C and D were tested for the respective muta-
tions, which confirmed AR inheritance (Figures 1C and
1D). Figure 2A depicts a schematic diagram of the muta-
tions, and the mutations are listed in Table 2.
No homozygousmutations in LRBA have been identified
in the 12 additional families with suspected AR-CVID and
weak linkage evidence. However, our sequencing efforts
have been limited to identifying mutations in the coding
regions of LRBA. Noncoding mutations might have been
missed in this gene that has more than 50 exons and spans
752,397 bp of genomic DNA.
LRBA-Deficient B Cells Show Defective Activation
and Survival
All individuals with homozygous LRBAmutations had low
levels of IgA and IgG in serum, and all, with the exception
of the individual who had the homozygous substitution
p.Arg1683*, had low levels of IgM (Table 1). In four of
the five affected individuals, counts of CD19þ B cells
were normal. Phenotypic analysis of B cell subsets
revealed a strong reduction of IgMþ CD27þ marginal-
zone-like B cells and IgGþ/IgAþ CD27þ switched-memory994 The American Journal of Human Genetics 90, 986–1001, June 8,B cells (Figure 3 and Table 1). Although IgM expression
in CD27 cells was higher in B cells of P1 and P3 than in
control cells analyzed in parallel, the proportion of transi-
tional B cells in P1 (1.7% of CD19þ cells) was not larger
than that in the control (0.5%–6% of CD19þ cells).
Switched-memory B cells as defined by CD19þCD27þ
IgM were low in all affected individuals tested (Table 1).
To test whether the defect in B cell development
correlates with defective B cell activation and/or im-
munoglobulin production, naive B cells from healthy
controls and individuals with homozygous LRBA muta-
tions were stimulated with anti-IgM, CD40L, BAFF, and
CpG oligonucleotide (ODN). Stimulated naive B cells
from healthy donors and individuals with heterozygous
LRBA mutations showed robust IgG production in vitro,
whereas naive B cells from three of the homozygous
affected individuals produced extremely low levels of
IgG (Figure S5). These results were confirmed when
B cells of P1 were stimulated with CD40L combined with
IL-21 or IL-4; under these conditions, IgG, IgA, and IgM
secretion was reduced (Figure S5). In agreement with
this, lymphocyte analysis after stimulation with CD40L
and IL-4 or IL-21 showed poor cell survival and a dramatic2012
Figure 4. Evaluation of Autophagy in
LRBA-Deficient and Control Cells
(A) In the top left panel, an image of a B
cell from a control shows a normal ultra-
structural morphology with well-defined
mitochondria (M), Golgi apparatus (G),
and ER (N, nucleus). An image from a B
cell from P4 shows increased areas of Golgi
apparatus (top right panel). Centrioles
(arrow) were frequently found in the cyto-
plasm of B cells from P4 (bottom left
panel), and accumulation of autophago-
somes (indicated by white asterisks) in
the cytoplasm was also frequently seen
(bottom right panels). Scale bars represent
1 mm.
(B) Autophagic flux showing the colocali-
zation of LC3 and LysoID in the presence
or absence of the lysosomal inhibitors
E64d/pepstatin on PBMCs (Inh). Cells
from P3 (red) show low levels of colocaliza-
tion of LC3 and LysoID in all conditions
tested. Error bars are shown and show the
variation in LysoID and LC3 colocalization
displayed by the B cells acquired on the
Image Stream (n ¼ 20,000).
(C) Representative images of B cells from
a healthy control and individual P3 show
LC3 and lysoID colocalization.reduction in the proportion of developing plasmablast cells
(Figure S5). Lymphocyte proliferation in response to PWM
(Figure S5) was also affected, which supports the defect of
plasma cell development given that both processes are
tightly linked.The American Journal of HumanLRBA-Deficient EBV Cells Show
Increased Apoptosis
The defects observed in immuno-
globulin production and B cell dif-
ferentiation and proliferation might
be due to increased cell death. It
has been suggested previously that
LRBA has a role in apoptosis.26 We
explored the susceptibility to apo-
ptosis in LRBA-deficient EBV cells
and analyzed the amount of apo-
ptotic cells after serum depriva-
tion. In EBV cells derived from
individuals P2 and P3, the proportion
of apoptotic cells increased signifi-
cantly after serum depletion;
however, in cells from three healthy
controls, the proportion of apoptotic
cells showed only a slight increase
(Figure 2C).
LRBA-Deficient B Cells Show
Reduced Autophagy
Autophagy is the major process by
which lysosomes degrade cellularmaterial and is cytoprotective. In its absence, mammalian
hematopoietic cells are prone to cell death.34 Because
serum starvation of LRBA-deficient cells caused increased
apoptosis, we hypothesized that LRBA deficiency would
affect autophagy. Furthermore, there are homologs ofGenetics 90, 986–1001, June 8, 2012 995
LRBA with lysosomal functions, and mice with mutations
in lysosomal proteins have similar phenotypes to mice
with mutations in the autophagic pathway.35 To detect au-
tophagosomes, we first compared LRBA-deficient B cells
with healthy controls by electronmicroscopy. The controls
showed a normal morphology and well-definedmitochon-
dria, Golgi apparatus, and endoplasmic reticulum (ER) (Fig-
ure 4A, top left). This was in stark contrast with individual
P4’s B cells, which showed increased areas of Golgi appa-
ratus (‘‘G’’ in Figure 4A). Furthermore, we observed that
many cells showed centrioles and accumulation of auto-
phagosomes (Figure 4A, bottom).
Using a recently published technique to detect the auto-
phagic flux in primary cells and cell lines by measuring the
proportion of cells with autolysosomes, defined by the co-
localization of both LC3 and a lysosomal marker,36 we
found that LRBA-deficient B cells have a significantly
reduced ability to induce autophagy in response to starva-
tion (Figure 4B). Figure 4C shows representative images of
B cells from one healthy donor and from individual P3.
Additionally, autophagy in individual P2 was reduced
(Figure S4). Data from individuals P2 and P3 cannot be
pooled because their samples were obtained under
different conditions. Interestingly, although lysosomal
content and LC3-positive autophagosomes were increased,
colocalization of these markers was reduced (data not
shown). Together with the electron microscopy data, these
results suggest that autophagic flux is impaired and does
not reach completion possibly because either the fusion
between autophagosomes and lysosomes is impaired or
lysosomes are not functional. Therefore, cells are accumu-
lating autophagosomes and LC3-containing vesicles,
which might contribute to cell death.Discussion
Homozygous mutations in LRBA cause a syndrome charac-
terized by early-onset hypogammaglobulinemia with
autoimmunity and inflammatory bowel disease. Affected
individuals show reduced levels of at least two immuno-
globulin isotypes (IgM, IgG, or IgA) and suffer from recur-
rent infections, autoimmunity, and chronic pulmonary
and gastrointestinal disorders. We identified five individ-
uals harboring four distinct mutations in LRBA (Table 2).
Three of these mutations are probably functional null
mutations because they represent either premature stop
codons (before the principal domains of LRBA) or a large
deletion. None of the mutations appear to disrupt
MAB21L2 (MIM 604357), which is nested in LRBA.37 No
previous study has reported LRBA germline mutations
associated with any disease, but somatic mutations of
LRBA have been reported in breast cancer.38
The following reasons led us to suspect LRBA as the
affected gene in family A. (1) The first study of LRBA
showed that LRBA is inducible by lipopolysaccharide
(LPS), a component of bacteria that triggers an immune996 The American Journal of Human Genetics 90, 986–1001, June 8,response.39 Although a portion of the sequence of LRBA
cDNA was first discovered and deposited in GenBank in
1992,40 Wang et al., were the first to clone a full-length
cDNA, and they proposed the current, descriptive name
‘‘LPS-responsive, beige-like anchor gene.’’39 (2) LRBA
shares some homology with a protein in the BCL family,
and the fact that some proteins in that family are involved
in B cell lymphomas indicates that LRBA is likely to be
active in B cells.41 (3) LRBA shares substantial homology
with LYST (MIM 606897), a lysosomal protein defective
or absent in another primary immunodeficiency, Chediak-
Higashi syndrome (CHS [MIM 214500]),42 a disease char-
acterized in part by large lysosomal granules in leukocytes
and giant melanosomes in melanocytes. Both mice and
humans with CHS have normal levels of immunoglobulins
and generally normal B cell function.43,44 (4) FAN (MIM
603043), another paralog of LRBA, is part of a pathway
connecting CD40 (an important signaling molecule for
B cells, monocytes, and other cells [MIM 109535]) to
signaling for apoptosis via the sphingomyelin-ceramide
pathway.45,46
LRBA is expressed in different cancer cell lines.26
Figure S6 shows that LRBA expression is widely distributed
in different immune and nonimmune tissues. Although
three different isoforms of murine Lrba have been
described, there are no convincing data showing the exis-
tence of more than one isoform of LRBA. The NCBI does
list two isoforms: RefSeq NP_001186211.2 (isoform 1;
2,851 amino acids) and NP_006717.2 (isoform 2; 2,863
amino acids). These differ in a dubious exon (exon 39),
and we believe that isoform 1 is the principal LRBA isoform
in B cells.
We show (Figure S6) that LRBA is expressed in many
tissues. This is mostly consistent with an earlier study by
Dynomin et al. and is consistent with the expression atlas
BioGPS.41,47 This atlas shows that LRBA is much more
highly expressed in immune cells, including T cells and
B cells, than in other tissues. The original study on murine
Lrba showed that at least one isoform is expressed in most
tissues.39 It is interesting to contrast the wide expression
pattern of Lrba with that of its paralog, Nbea, which has
high levels of expression in brain and endocrine tissues
and low or no expression in other tissues.48 Perhaps
NBEA (MIM 604889) carries out some functions of LRBA
in nonimmune cells of LRBA-deficient individuals. An
overlap in LRBA and NBEA expression and function could
reconcile the fact that autophagy happens in most cell
types with our findings that LRBA-deficient lymphocytes
have a defect in autophagy but that the phenotype of
LRBA-deficient individuals is limited to the immune
system.
Little is known about the exact function of LRBA in
human biology. LRBA is a member of the BEACH-WD40
protein family.49 Members of this family include LYST,
which is involved in the regulation of lysosome-related
organelle size and movement;42 NBEAL2 (MIM 614169),
which was recently identified as the gene mutated in2012
gray platelet syndrome (MIM 139090);50–52 FAN (MIM
603043), a protein involved in TNFR signaling; and
NBEA (MIM 604889), a protein with A-kinase anchoring
and vesicular release at the neuromuscular junc-
tion.42,45,53,54 Interestingly, LRBA contains an A-kinase
anchoring protein (AKAP) motif.55 AKAPs have an affinity
for the regulatory subunits of protein kinase A (PKA RI or
PKA RII) and other signaling enzymes such as protein
kinase C (PKC). Their main function is to compartmen-
talize these signaling molecules to distinct membranes
and organelles.55 The repeated WD40 domain is located
at the C-terminal end and is preceded by the BEACH
and Plekstrin Homology (PH) domains.49 The WD40
domain is highly conserved between species and is one
of the most abundant domains in eukaryotic organisms.
WD40 domains can bind multiple partners in dif-
ferent ways.56 They are important for protein-protein
and protein-DNA interactions, and they participate in
multiple cellular processes, such as signal transduction,
vesicular trafficking, cytoskeleton assembly, the cell cycle,
apoptosis, chromatin dynamics, and transcriptional
regulation.56 The precise function of the BEACH domain
is unknown; it might be important for protein-protein
interaction.49 The PH domain of LRBA is weakly
conserved. An intramolecular interaction between BEACH
and PH domains has been shown, and both domains
might therefore be important for protein folding and
signaling.57
The p.Ile2657Ser substitution in P1 and P2 affects the
WD40 domain of LRBA. However, the binding partners
for the LRBAWD40 domain are unknown. Moreover, the
p.Ile2657Ser substitution affects protein expression, sug-
gesting that this amino acid substitution affects the
stability of LRBA. Because p.Ile2657 is a conserved residue
(Figure S2), it might be important for protein folding or
might affect the binding with LRBA interaction partners.
The p.Arg1683* change, if translated, would lead to
a shorter protein lacking 1,180 residues at the C-terminal
end of LRBA. This substitution would affect the expression
of the PH, BEACH, and WD40 domains of LRBA. We did
not detect any shorter form of LRBA in P3, and therefore,
the shortened mRNA might be subject to nonsense-medi-
ated decay. The mutation found in P4 introduces a stop
codon at position 59 of the protein. If translated, it would
give a very short product unlikely to have any function. In
the case of P5, the protein should not be translated because
the large deletion eliminates the translation start site
(Figures 1D and 2A).
Overall, fewer than 20% of individuals with CVID have
an affected relative.2 However, AR simplex cases, including
three of the five affected individuals in our study, might
not be recognized as familial cases. Among the family
members summarized in Figure 1, the 15 individuals
with heterozygous mutations are all asymptomatic. We
infer that, unlike in the case of TNFRSF13B, LRBA is not
likely to play a prominent role in dominantly-inherited
antibody deficiencies.The AmeAll homozygous individuals with LRBA deficiency
showed reduced counts of switched-memory B cells, as
has been reported for individuals with CVID. P1 and P3
also lacked marginal-zone-like B cells. P4 had reduced
counts of total B cells. P5 had low T cell levels. Natural
killer (NK) cell counts were low in P3 and P4. Although
we measured a reduced proportion of the CD16þCD56þ
NK subpopulation in P3, no functional NK cell defect
was detected for this individual as measured by normal
CD107a translocation (data not shown).58
LRBA-deficient B cells culturedunder conditions favoring
class-switch recombination and plasmablast development
failed to proliferate, differentiate into antibody-secreting
cells, and induce expression of markers characteristic of
plasmablasts.Duringantigen recognition,B cellsproliferate
for clonal expansion, a process important for differentia-
tion to memory or plasma cells.59 Data provided here indi-
cate that LRBA deficiency leads to defects in B cell differen-
tiation.Analysis of tumor cells suggests that LRBApromotes
proliferation and cell survival.26 Our results showing
increased susceptibility to apoptosis in LRBA-deficient
EBV cells support this interpretation.
LRBA deficiency resulted in reduced autophagy as shown
by the abnormal accumulation of organelles in B cells. This
observation was confirmed by the low colocalization of
LC3 with lysosomes. These data suggest that LRBA plays
a role in autophagy and that the increased susceptibility
to apoptosis might be a consequence of defective auto-
phagy. Supporting the effect of autophagy on B cell func-
tion, mice deficient in the autophagy-related Atg5 show
defects in B cell development.60
Because autophagy and apoptosis have been reported to
be defective in autoimmune conditions such as systemic
lupus erythematosus,61 it is tempting to speculate that
the autoimmune features seen in LRBA-deficient individ-
uals are attributable to defective autophagy and increased
apoptosis. Additionally, defects in autophagy genes have
been associated with several conditions in humans, for
example, X-linked myopathy with excessive autophagy
(XMEA [MIM 310440]), Pompe disease (MIM 232300),
and Parkinson disease (MIM 600116),62–64 suggesting
that inherited defects in autophagy might lead to tissue-
specific defects in cellular function. Additionally, autoph-
agy has been linked to B cell germinal-center number
and size in mice with a heterozygous deletion of the
gene encoding the known autophagy protein beclin-1
(also knownasAtg6). Thesemicehave a reducedoccurrence
of autophagy and a reduced number and size of germinal
centers.65 Lysosomal stability is known to be associated
with germinal-center stability,66 but we could not mecha-
nistically link LRBA to germinal-center formation. The
description of beclin-1-heterozygous mice suggested the
hypothesis that deficiency of LRBA would lead to reduced
autophagy in lymphocytes. If cells are under stress and
autophagy is reduced, then the more direct alternative,
apoptosis, should be increased. Interestingly, the data re-
garding autophagy and apoptosis (Figure 4 and Figure S4)rican Journal of Human Genetics 90, 986–1001, June 8, 2012 997
are consistent with the hypothesis that the lack of LRBA
disrupts the autophagy pathway that includes beclin-1.67
We were enticed by the observation that several LRBA
homologs, including LYST, are known to function in lyso-
somal vesicles.44,68,69 The movement of lysosomal vesicles
in which these proteins participate might be part of an
autophagy process. The principal subcellular-localization
study was done by Wang et al.39 on the cell line RAW
264.7. They showed that LRBA colocalized with lyso-
somes, the trans-Golgi network, the ER, the perinuclear
ER, and endocytic vacuoles. These localizations are consis-
tent with a role for LRBA in autophagy because these
organelles either play a role in the completion of the auto-
phagosomal flux or are cleared by autophagy in the
following ways. (1) Autophagosomal content is delivered
to the lysosome; in this manuscript and our previous
work, we measure autophagy levels by quantifying the
extent of colocalization of lysosomal and autophagosomal
markers.36 (2) Recent studies have shown show that auto-
phagosomal membranes originate at the ER.70,71 More-
over, the existence of autophagy of ER components
(ER-phagy) has been suggested.72 (3) The endocytic and
autophagic pathways are linked, and components of func-
tional endomembrane trafficking, the secretory pathway,
and fusion machinery have been shown to have an
impact on autophagy.73 (4) In work by Nishida et al.,
which describes an Atg5/7 independent pathway, auto-
phagosome-like structures appear near the Golgi appa-
ratus.74 Furthermore the Golgi-endosomal system is also
thought to contribute to the Atg5/7-dependent conven-
tional formation of autophagosomes.75 Finally, there is
a possibility that clearance of the Golgi apparatus might
be mediated by autophagy, possibly explaining the accu-
mulation of Golgi in the absence of LRBA. The observed
colocalizations do not identify the exact role of LRBA in
the autophagic flux; further molecular studies are
required.
Our study demonstrates the importance of LRBA for the
human immune system and its role in host defense and
autoimmune and autoinflammatory conditions. The
finding that mutations in LRBA result in a severe pheno-
type of hypogammaglobulinemia and autoimmunity in
four different families adds to the understanding of the
participation of LRBA in apoptosis and suggests that indi-
viduals with the clinical phenotype described above
should be screened for LRBA mutations. In our study, all
affected individuals were clinically diagnosed with CVID,
but the clinical data of LRBA deficiency show autoimmu-
nity since early childhood. Our data support the participa-
tion of LRBA in apoptosis; however, future work is
required for fully understanding the exact functions of
LRBA.Supplemental Data
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